SEC Stock Data Quick Answer Allegiant Travel CO reported Total Revenue of $2.61 billion for fiscal year 2025. Allegiant Travel CO Total Revenue — Annual History Fiscal Year Total Revenue YoY Change 2025 $2.61B +3.7% 2024 $2.51B +0.1% 2023 $2.51B +9.0% 2022 $2.30B +34.8% 2021 $1.71B +72.5% 2020 $990.07M -46.2% 2019 $1.84B +10.4% 2018 $1.67B +10.3% 2017 $1.51B … Read more
Quick Answer Allegiant Travel CO reported Total Revenue of $2.61 billion for fiscal year 2025. Allegiant Travel CO — Key Financials by Year Metric 2025 2024 2023 2022 2021 2020 Total Revenue $2.61B+3.7% $2.51B+0.1% $2.51B+9.0% $2.30B+34.8% $1.71B+72.5% $990.07M-46.2% Revenue (ASC 606) $2.32B+4.8% $2.22B-4.6% $2.32B+8.7% $2.14B+35.4% $1.58B+75.0% $902.19M-46.4% Net Income — — — — — — … Read more
Quick Answer Aligos Therapeutics, Inc. reported Shares Outstanding of 6.18 million shares for fiscal year 2025. Aligos Therapeutics, Inc. Shares Outstanding — Annual History Fiscal Year Shares Outstanding YoY Change 2025 6.18M +59.9% 2024 3.86M -95.2% 2024 79.90M +2559.9% 2023 3.00M -93.0% 2022 42.92M +0.5% 2021 42.69M +12.0% 2020 38.12M +870.5% 2019 3.93M — Quarterly … Read more
Quick Answer Aligos Therapeutics, Inc. reported Operating Income of -$87.98 million for fiscal year 2025. Aligos Therapeutics, Inc. Operating Income — Annual History Fiscal Year Operating Income YoY Change 2025 -$87.98M +1.3% 2024 -$89.15M -1.2% 2023 -$88.13M +9.7% 2022 -$97.58M +24.0% 2021 -$128.32M -31.2% 2020 -$97.83M -81.0% 2019 -$54.04M — Quarterly Operating Income Quarter Ending … Read more
Quick Answer Aligos Therapeutics, Inc. reported R&D Expense of $69.45 million for fiscal year 2025. Aligos Therapeutics, Inc. R&D Expense — Annual History Fiscal Year R&D Expense YoY Change 2025 $69.45M -1.2% 2024 $70.27M -3.8% 2023 $73.04M -14.1% 2022 $85.08M -18.3% 2021 $104.15M +30.4% 2020 $79.89M +81.4% 2019 $44.04M — Quarterly R&D Expense Quarter Ending … Read more
Quick Answer Aligos Therapeutics, Inc. reported Stockholders Equity of $53.55 million for fiscal year 2025. Aligos Therapeutics, Inc. Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 $53.55M +284.8% 2024 -$28.97M -131.5% 2023 $92.08M -11.4% 2022 $103.90M -43.8% 2021 $184.73M -16.0% 2020 $220.04M +439.1% 2019 -$64.89M -372.0% 2018 -$13.75M — Quarterly Stockholders … Read more
Quick Answer Aligos Therapeutics, Inc. reported Cash and Equivalents of $18.30 million for fiscal year 2025. Aligos Therapeutics, Inc. Cash and Equivalents — Annual History Fiscal Year Cash and Equivalents YoY Change 2025 $18.30M -50.5% 2024 $37.00M -72.7% 2023 $135.70M +66.8% 2022 $81.35M -56.5% 2021 $186.82M -15.2% 2020 $220.38M +216.8% 2019 $69.56M — Quarterly Cash … Read more
Quick Answer Aligos Therapeutics, Inc. reported Total Assets of $88.53 million for fiscal year 2025. Aligos Therapeutics, Inc. Total Assets — Annual History Fiscal Year Total Assets YoY Change 2025 $88.53M +26.3% 2024 $70.09M -53.7% 2023 $151.53M +3.3% 2022 $146.69M -37.7% 2021 $235.37M -11.3% 2020 $265.30M +81.1% 2019 $146.52M — Quarterly Total Assets Quarter Ending … Read more
Quick Answer Aligos Therapeutics, Inc. reported Diluted EPS of $2.45 per share (loss) for fiscal year 2025. Aligos Therapeutics, Inc. Diluted EPS — Annual History Fiscal Year Diluted EPS YoY Change 2025 -$2.45 +88.3% 2024 -$20.94 +38.8% 2023 -$34.20 -1420.0% 2022 -$2.25 — Quarterly Diluted EPS Quarter Ending Diluted EPS YoY QoQ September 30, 2025 … Read more
Quick Answer Aligos Therapeutics, Inc. reported Net Income of -$24.19 million for fiscal year 2025. Aligos Therapeutics, Inc. Net Income — Annual History Fiscal Year Net Income YoY Change 2025 -$24.19M +81.6% 2024 -$131.21M -49.6% 2023 -$87.68M +8.7% 2022 -$96.05M +25.2% 2021 -$128.33M -18.2% 2020 -$108.54M -107.7% 2019 -$52.26M — Quarterly Net Income Quarter Ending … Read more